Journal of Clinical & Experimental Pharmacology

Journal of Clinical & Experimental Pharmacology
Open Access

ISSN: 2161-1459

+44 1202068036

Abstract

The Antianginal Agent Ranolazine Inhibits Mitochondrial β-Oxidation Pathway

Khazraei H, Mirkhani H and Akmali M

Abstract Backgrounds: Ranolazine had two main functions: blocking cardiac late sodium channels and / or inhibition of 3- ketoacyl coenzyme A thiolase, an important enzyme in -oxidation of fatty acids. Diabetic cardiomyopathy is a complication, defined as cardiac dysfunction without the involvement of epicardial vessels. In this study, the effect of ranolazine on fatty acid oxidation was investigated in diabetic rats induced by streptozotocin. Methods: After 8 weeks of diabetic induction, the effect of ranolazine on fatty acid oxidation rate was studied. Statistical data were analyzed using Mann-Whitney test. Results: The activity of -oxidation enzymes were inhibited by ranolazine in the normal rat hearts significantly, while no significant inhibition was seen in diabetic ones. Conclusion: Our data suggest that the clinical efficacy of ranolazine in diabetic patients is associated with a mechanism other than inhibition of the -oxidation pathway activity, although various hypotheses exist in the literature.

Top